Skip to main content
Clinical Trials/IRCT201612201031N20
IRCT201612201031N20
Completed
Phase 2

The effect of intramyocardial transplantation of autologous bone marrow derived MNC (MonoNuclear Cell) and CD133+ cells comparison to placebo, on LVEF in MI patients, A Phase II/III, Multicenter, Placebo-Controlled, Randomized, Double-Blind Clinical Trial

Royan Institute0 sites90 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Royan Institute
Enrollment
90
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 18\-75 years; First ST elevation myocardial infarction (STEMI) 10 days \- 3 months; Post\-acute myocardial infarction (AMI) left ventricular ejection fraction (LVEF) as assessed by echocardiography: 20%\-45%; Target lesion must be located in the left anterior descending (LAD) section; Coronary artery bypass graft (CABG) candidate; At least 4 akinetic segments (assessed by stress echocardiography).
  • Exclusion criteria:
  • History of prior AMI; Active infection; History of recurrent infection; Positive test for syphilis (RPR); Hepatitis B and C (HBsAg, anti\-HBc, anti\-HCV); HIV or HTLV\-1; Documented terminal illness or malignancy; Documented autoimmune disease; Pulmonary edema; Urgent or emergency CABG; Systolic blood pressure \<80 mmHg; 4000 \> leukocytes (µL) \>15000; AST \>100 IU/L or ALT \>100 IU/L; Hemoglobin \<10 g/dL; Platelets \<100,000/µL; INR \>1\.8

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials